June 14, 2011 – Positron, a molecular imaging company specializing in the field of nuclear cardiology, is relocating its corporate headquarters, research and development and product manufacturing facilities to Noblesville, Ind. Positron also plans to develop a high-energy 70 MeV cyclotron project and radiopharmaceutical manufacturing facility, also to be located in Noblesville.

Positron is proposing to make a capital investment of approximately $55 million for this project in conjunction with significant economic development incentives from the city of Noblesville and the state of Indiana, as well as various other project financing opportunities.

This cyclotron, once completed, will be the highest energy commercial cyclotron for isotope production within the United States and will advance Positron’s objectives for the production of medical isotopes and radiopharmaceuticals used in cardiac positron emission tomography (PET) imaging, diagnostic and therapeutic medical radiopharmaceuticals.

Positron’s development plans are expected to create more than 80 jobs in Noblesville over the next three to five years, a majority of which would be highly-skilled, professional positions. In addition, the city is expected to realize further economic benefits through complementary businesses locating in Noblesville in order to be in close proximity to this unique facility. The company believes Noblesville to be the ideal choice for expansion plans based on its growing economy, strategic location and the city’s commitment to promoting a thriving healthcare and technology environment.

Positron, the city of Noblesville and the state of Indiana are working to finalize a definitive agreement regarding the proposed incentive package for this project.

For more information: www.positron.com


Related Content

News | FDA

March 18, 2026 — FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology, has announced that the U.S ...

Time March 24, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | PET-CT

Feb. 27, 2026 — A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little ...

Time February 26, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | Prostate Cancer

Sept. 26, 2025 — A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...

Time September 18, 2025
arrow
News | Nuclear Imaging

May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...

Time May 06, 2025
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
Subscribe Now